ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jan 04, 2022 11:10 JST
Source:
Apollomics, Inc.
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group
Foster City, CA, and Hangzhou, China, Jan 04, 2022 - (ACN Newswire) - Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer of Apollomics, was recently appointed to Chairman of the Board for the BayHelix Group, effective January 2022.
"I am honored to be selected by my peers to help guide the BayHelix Group as it continues to foster biotech innovations and expand business opportunities within the broad life sciences ecosystem globally," said Dr. Yu. "For 20 years, the BayHelix group has been an instrumental connection between emerging Chinese companies and the rest of the world. As a dual U.S. and China biotechnology company focused on the development of innovative therapies for cancer treatment, Apollomics has been actively involved with BayHelix since our inception. I look forward to offering my expertise and insights, and working with my distinguished BayHelix board of directors and fellow members, to further our goals towards connecting biopharmaceutical companies around the world."
About BayHelix Group
The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix aspires to foster and create business opportunities, supply and nurture leaders for the community, and network and share information and experience among its members. The diverse membership base covers many of the world's top pharmaceutical and biopharmaceutical companies, leading professional services and investment firms, as well as start-up biotech companies in China and the US. BayHelix membership is by-invitation only. Over two thirds of members are C-level executives. The majority of them are cross trained in science and business as well as bilingual in Chinese and English. BayHelix has become an influential organization that connects emerging biopharmaceutical companies in China to their counterparts around the world.
About Apollomics Inc.
Apollomics Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting and immuno-oncology agents. The Company's product pipeline has several programs at different stages of development, including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Apollomics has operating entities in Foster City, California, USA, Hangzhou and Shanghai, China. For more information, please visit www.apollomicsinc.com.
Contact Information:
Investor Contact:
Wilson W. Cheung
Chief Financial Officer
(650) 209-4436
wcheung@apollomicsinc.com
U.S. Media Contact:
Remy Bernarda
Corporate Communications
(415) 203-6386
remy.bernarda@apollomicsinc.com
China Media Contact:
Porda Havas International Finance Communications Group
Kelly Fung
General Manager
(852) 3150 6763
kelly.fung@pordahavas.com
Source: Apollomics, Inc.
Sectors: BioTech, Clinical Trials
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Honda and IBM sign Memorandum of Understanding to Explore Long-term Joint Research and Development of Semiconductor Chip and Software Technologies for Future Software-Defined Vehicles
May 15, 2024 14:30 JST
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
May 15, 2024 11:19 JST
SMEIC Proposes to Acquire Shanghai Prime: A Catalyst for Developing a New Dual-Wheel Driver Pattern
May 14, 2024 21:54 JST
DENSO and Certhon Introduce Artemy, A Fully Automated Cherry Truss Tomato Harvesting Robot
May 14, 2024 11:02 JST
Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
May 13, 2024 18:32 JST
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures
May 13, 2024 17:06 JST
Ogier and TOYOTA GAZOO Racing triumph again
May 13, 2024 14:36 JST
Spa points haul for TOYOTA GAZOO Racing
May 13, 2024 13:56 JST
DOCOMO to Launch NTT DOCOMO GLOBAL for Global Expansion
May 10, 2024 18:13 JST
Release of "Fugaku-LLM" - a large language model trained on the supercomputer "Fugaku"
May 10, 2024 12:20 JST
Paltalk, Inc. Reports Slight Increase in Revenue and 33% Reduction in Net Loss for First Quarter 2024
May 09, 2024 20:39 JST
Cordlife Accelerates Lab and Technical Staff Recruitment to Rebuild Foundation and Strengthen Core Processes in Singapore
May 09, 2024 19:00 JST
Honda Opens New R&D Facility in Bengaluru to Accelerate Electrification in India
May 09, 2024 14:13 JST
Fujitsu introduces "explainable AI" for use in genomic medicine and cancer treatment planning
May 09, 2024 10:41 JST
Mitsubishi Heavy Industries Increases Dividends on Back of Historically High FY2023 Results, Releases FY2024 Guidance
May 08, 2024 14:27 JST
Rome becomes the first European city to offer open loop transit payments to JCB Cardmembers
May 08, 2024 12:00 JST
NEC X Invests in Public Safety Startup Multitude Insights, Scaling AI-Powered Collaboration and Information Sharing for Law Enforcement
May 08, 2024 10:24 JST
ServiceNow and Fujitsu announce strategic commitment to launch innovative cross-industry solutions
May 08, 2024 08:52 JST
Fujitsu launches mainframe modernization automation service for the Japanese market
May 07, 2024 17:53 JST
MHI Agrees to Collaborate with Chiyoda Corporation for Licensing of CO2 Capture Technologies
May 07, 2024 13:49 JST
More Latest Release >>
Related Release
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
March 30 2023 20:29 JST
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer
July 26 2022 09:17 JST
Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022
January 12 2022 09:25 JST
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
November 22 2021 10:40 JST
Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial
October 01 2021 10:00 JST
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102
August 10 2021 11:53 JST
APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH
May 20 2021 13:36 JST
Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer
March 09 2021 10:35 JST
Apollomics, Inc Announces Enrollment of First Patient in Phase 1 Clinical Trial of APL-106 (uproleselan injection) in China
March 04 2021 11:30 JST
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
February 12 2021 13:00 JST
More Press release >>